Physician profile
Ni Sun
NPI 1487153417
$1,889.51
in general payments reported to CMS, 2019-2025
15 companies · $721 in 2025
The $721 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $144 · 2024: $899 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $668.89 | 2024-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $219.23 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $202.93 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $166.12 | 2022-2023 | Farxiga |
| Pfizer INC. | $97.19 | 2024 | |
| Ardelyx, INC. | $97.03 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.06 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $87.60 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $72.56 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $57.22 | 2023 | |
| Glaxosmithkline, LLC. | $41.47 | 2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $32.00 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2025 | |
| Aimmune Therapeutics, INC. | $20.14 | 2024 | |
| Lilly USA, LLC | $16.69 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ni Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.